There is an ongoing controversy surrounding how return-on-investment (ROI) of disease management programs is calculated. Historically there's been a high level of difficulty measuring the financial impact of DM programs because of unclear parameters. To make matters worse, changes in health costs over time cannot necessarily be attributed to just one cause.
What are the true cost savings of specific disease management programs? And what is the best way to calculate the ROI of your DM programs? Is there a standardized methodology for evaluating programs? Do you need to examine only healthcare cost savings or the impact on the patient’s day-to-day functioning, absenteeism and overall productivity?
Listen to "Disease Management ROI: Benchmarks, Metrics, and Case Studies for Success," a May 3, 2007 audio conference now available on CD-ROM and hear experts on disease management analysis discuss disease management and ROI.
You'll hear from the following industry experts:
- Ron Z. Goetzel, Ph.D., Director, Cornell Institute for Health and Productivity Studies
- Matthew McGinnis, Senior Director, Center for Health Research, Healthways
- Thomas W. Wilson, Ph.D., Epidemiologist, Trajectory HealthCare
- The ROI Problem… The Key Principles in Calculating ROI
- Lessons Learned in DM ROI Calculation
- How the Success of Disease Management Programs is Measured
- How to Establish Metrics for Evaluating DM Programs
- Common Mistakes in Measuring ROI
- Which Disease Management Programs Have a Higher ROI?
- ROI Case Studies from Healthways, One of the Largest Providers of DM Programs
- Question and Answer Session
Who Will Benefit From This Audio Conference?
CEOs, COOs, strategists, planners, business development, DM providers, product managers, consultants, hospital executives, managed care organizations, health insurers, employers, CMOs, vice president quality, vice president medical management, DM executives, DM program managers, case managers, DM software developers, human resource benefit managers, employee health services managers, workplace wellness managers, health educators, analysts, directors of members services, network planners, pharmaceutical companies, medical device manufacturers and healthcare technology companies.
About our Panelists:
Ron Z. Goetzel
Ron Z. Goetzel wears two hats. He is both the founding Director of the Cornell University Institute for Health and Productivity Studies and Vice President of Consulting and Applied Research at Thomson Medstat. The mission of the IHPS is to bridge the gap between academia, the business community, and the healthcare policy world – bringing academic resources into policy debates and day-to-day business decisions, and bringing health and productivity management issues into academia. At both Cornell and Medstat, Dr. Goetzel is responsible for leading innovative research projects and consulting services for healthcare purchaser, managed care, government, and pharmaceutical clients interested in conducting cutting-edge research focused on the relationship between health and well-being, and work-related productivity. He is a nationally recognized and widely published expert in health and productivity management, return-on-investment (ROI), data analysis, program evaluation and outcomes research.
Over the past 20 years, Dr. Goetzel’s work has focused on large-scale evaluations of health promotion, disease prevention, demand and disease management programs. He is principal investigator for Medicare’s Senior Risk Reduction Demonstration (SRRD) and New Opportunities for Healthy Aging in Medicare (NOHAM) project. He is also principal investigator for a project sponsored by the National Heart, Lung and Blood Institute (NHLBI) focused on obesity prevention and management at the Dow Chemical Company. For the Centers for Disease Control and Prevention (CDC), Dr. Goetzel is the principal investigator for a New York City-based project supporting collaborative efforts between the private and public sectors in health promotion and disease prevention programs directed at employers. He is also leading a Health and Productivity Management (HPM) benchmarking and employer “tools” project for the CDC. He has functioned as principal investigator for research efforts directed at employer HPM initiatives at Applied Materials, Boeing, ChevronTexaco, Pacific Bell, Citibank, Johnson & Johnson, IBM, Procter & Gamble, Florida Power & Light, Duke University, Sharp Health Care, Saturn Corporation, PG&E, The Associates and HERO. He has also been a principal on several health and disease management evaluation projects for Blue Cross Blue Shield Association Federal Employee Program (FEP), General Electric Company, Ford, PSE&G, Motorola, Delta Airlines, Lucent, International Truck and Engine, First Tennessee Bank and Texas Instruments. His pharmaceutical industry work with Aventis, Schering-Plough, Pfizer, Astra Zeneca, Bristol Myers Squibb, and Eli Lilly has focused on establishing the health and productivity cost burden of certain illnesses.
Before joining Medstat in 1995, Dr. Goetzel was Vice President of Assessment, Data Analysis and Evaluation Services at Johnson & Johnson Health Care Systems. Before joining Johnson & Johnson, Dr. Goetzel was one of the original members of the core development and marketing group at Corporate Health Strategies, currently a division of Ingenix. Earlier in his career, Dr. Goetzel was the Medical School Education Program Evaluator at the Albert Einstein College of Medicine, where he was appointed to the Psychiatry faculty.
Dr. Goetzel earned his doctorate in Organizational and Administrative Studies and his M.A. in Applied Social Psychology from New York University (NYU), and his B.S. degree in Psychology from the City College of New York (CCNY). He is located in Washington, DC.
Matthews McGinnis currently leads the Business Decision Support group within the Center for Health Research team for Healthways. The role of the Business Decision Support group is to support internal senior management and other stakeholders with rapid analytics to inform decision makers and help direct the organization. His team’s mission focuses on leveraging healthcare analytics and predictive modeling to better understand and optimize the drivers of healthcare outcomes, ultimately demonstrating the significant value that Healthways delivers.
McGinnis has over ten years of experience in the healthcare industry. He joined Healthways in 2000 as a part of the finance department, supporting customers through outcomes reporting and analysis. He has served as a Manager and Director within the Finance department. Duties included the support of customers as well as the management of a team of analysts who were responsible for reporting and other functions. He has co-authored and published several articles in peer reviewed journals with a focus on the outcomes in disease management. Prior to joining Healthways he was a Medical Economics Analyst for Cigna Healthcare in Franklin, Tennessee. McGinnis received his Bachelor of Accounting from the University of Florida.
Thomas Wilson, PhD, DrPH is a nationally known epidemiologist specializing in the evaluation of programs and products designed to understand and/or impact defined populations. These include disease management, case management, payment-for-performance programs, predictive algorithms, and electronic medical record use.
Wilson is the principal of Trajectory® Healthcare, LLC--a strategic epidemiologic consultancy firm. The firm has provided epidemiologic services to the Medicare program, State Medicaid Agencies, health plans, the Blue Cross Blue Shield Association, private foundations, care management vendors, and employer groups. He is currently the co-chair of the Patient Safety and Quality Committee of the Disease Management Association of America (DMAA), and a member of the editorial board of the Journal of Health and Productivity.
His former positions include the Corporate Epidemiologist at Anthem Blue Cross Blue Shield, faculty research positions at Columbia University and UC Berkeley, an NIH post-doctoral fellowship position in cardiovascular disease, and a Fulbright award lectureship. Publications range from contributor (and associate editor) to the encyclopedic Cambridge World History of Human Disease to commissioned works on disease management evaluation from both the DMAA and the AcademyHealth's State Coverage Initiatives, a program of the Robert Wood Johnson Foundation. Other writings have appeared in the American Journal of Hypertension, American Journal of Managed Care, Annals of Internal Medicine, Barron's Weekly, Cambridge University Press, Circulation, Disease Management, Duke University Press, Employee Benefit News, Health Affairs, Joint Commission Journal of Quality and Safety, Journal of the American Geriatric Society, Lancet, Statistics in Medicine, Journal of Health and Productivity, and others. He is also a frequent speaker at national meetings on the
uses of evaluation for care management program improvement and program impact.